Acta Med Port 2017 Jun 30;30(6):443-448. Epub 2017 Jun 30.
Serviço de Infeciologia. Hospital de Egas Moniz. Centro Hospitalar Lisboa Ocidental. Lisboa. Portugal.
Download full-text PDF
Medicine (Baltimore) 2001 Jan;80(1):54-73
Clinical Microbiology-Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
Visceral leishmaniasis is an endemic infection in Mediterranean countries, where it has become a frequent complication of acquired immunodeficiency syndrome (AIDS). The incidence of visceral leishmaniasis is increasing in Spain due to human immunodeficiency virus (HIV)-related cases, but some aspects of its epidemiology, clinical features, and management remain unknown. In addition, no comparative clinical studies about the disease in HIV-infected and non-HIV-infected patients have been reported. Read More
Clin Infect Dis 2011 Oct;53(7):e91-8
Rajendra Memorial Research Institute of Medical Science, Patna, Bihar.
Background: Reports on treatment outcomes of visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied the efficacy of liposomal amphotericin B in VL-HIV coinfection. We report the 2-year treatment outcomes of VL-HIV-coinfected patients treated with liposomal amphotericin B followed by combination antiretroviral treatment (cART) in Bihar, India. Read More
PLoS Negl Trop Dis 2018 05 25;12(5):e0006527. Epub 2018 May 25.
Public Health Department, Médecins Sans Frontières, Amsterdam, The Netherlands.
Background: North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and relapse rates than HIV-negative VL patients. Whereas secondary prophylaxis reduces the relapse rate, parasitological failure rates remain high with the available antileishmanial drugs, especially when administered as monotherapy. Read More
Clin Infect Dis 2015 Oct 30;61(8):1255-62. Epub 2015 Jun 30.
Médecins Sans Frontières, New Delhi Institute of Tropical Medicine, Antwerp, Belgium.
Background: There are considerable numbers of patients coinfected with human immunodeficiency virus (HIV) and visceral leishmaniasis (VL) in the VL-endemic areas of Bihar, India. These patients are at higher risk of relapse and death, but there are still no evidence-based guidelines on how to treat them. In this study, we report on treatment outcomes of coinfected patients up to 18 months following treatment with a combination regimen. Read More